Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although gastroenterologists are increasingly prescribing Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade and Abbott/Eisai's Humira for the treatment of Crohn's disease and ulcerative colitis, a high proportion of managed care organizations (MCOs) subject both drugs to multiple cost-control strategies to keep costs down and limit the use of the two biologic therapies.
The new Physician & Payer Forum primary market research report entitled The Emergence of New Biologic Treatment Options for Crohn's Disease and Ulcerative Colitis: Physician and Payer Attitudes includes forecasts on the future of biological therapy in the treatment of Crohn's disease and ulcerative colitis, based on the views of prescribers and MCO pharmacy directors. According to the report, nearly one-third of the 20 MCOs surveyed levy coinsurance charges on Remicade and Humira and most plans require prior authorization for each drug. More than half of the plans that cover both drugs also employ step-therapy protocols. The report also finds that six of the 20 MCOs surveyed plan to extend their step therapy requirements during 2008 for Remicade, and five of 19 MCOs will do the same for Humira.
"Despite prior authorization and step therapy protocols that MCOs have put into place, both Remicade and Humira are being increasingly prescribed to patients with Crohn's disease," said Cindy Mundy, Ph.D. director at Decision Resources. "Humira, which was approved for Crohn's disease in January, 2007, is rapidly gaining ground on Remicade in terms of physician perceptions of key measures. We also found that approximately half of surveyed gastroenterologists consider the two drugs to be equal in treating Crohn's disease."
The Emergence of New Biologic Treatment Options for Crohn's Disease and Ulcerative Colitis: Physician and Payer Attitudes is based on a U.S. survey of 101 gastroenterologists and 20 managed care organization pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/